SALCS 2022 | Updates in targeting mesothelin-expressing solid tumors

Mitchell Ho, PhD, National Institutes of Health, Bethesda, MD, comments on mesothelin as a target for CAR-T cells in solid tumors. Antibodies have been developed that enables CAR-T cells to penetrate the tumor, improving the efficacy of cellular therapies expressing mesothelin such as mesothelioma, ovarian and pancreatic cancer. Multiple clinical trials are additionally underway to assess these therapies. This interview took place at the 2022 San Antonio Liver Cancer Symposium (SALCS) in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.